Login to Your Account



Reverset Delay Of Phase III Sends Incyte Stock Reeling

By Karen Pihl-Carey


Thursday, September 29, 2005
News that the HIV drug Reverset needs another Phase II study, delaying pivotal trials, drove Incyte Corp.'s stock down by 41 percent Wednesday. The Wilmington, Del.-based company met with the FDA earlier this week to discuss Phase II data presented in July at an International AIDS Society conference in Rio de Janeiro, Brazil, as well as its plans to move into two Phase III trials. The agency, though, looking for confirmatory safety and efficacy data, requested another Phase II study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription